Skip to main content

Advertisement

SpringerLink
Log in

The German guidelines for the treatment of anxiety disorders

  • Invited Review
  • Published:
European Archives of Psychiatry and Clinical Neuroscience Aims and scope Submit manuscript

Abstract

A consensus group consisting of 36 experts representing 20 leading German specialist societies and patient self-help organizations developed evidence-based recommendations for the treatment of anxiety disorders in Germany. These were based on a systematic review of randomized controlled trials on anxiety disorders (n = 403) and on preexisting German and international guidelines. According to the consensus committee, anxiety disorders should be treated with psychotherapy or pharmacological drugs or a combination of both. Cognitive behavioral therapy (CBT) was regarded as the psychological treatment with the highest level of evidence. Psychodynamic therapy (PDT) was recommended for cases in which CBT was not effective or not available or in which PDT was the informed patient’s preferred option. First-line drugs for anxiety disorders include selective serotonin reuptake inhibitors and serotonin–noradrenaline reuptake inhibitors. After remission, medications should be continued for 6–12 months. When either drug or psychotherapy was not effective, treatment should be switched to the other approach or to a combination of both. For patients non-responsive to standard treatments, alternative strategies are suggested. When developing a treatment plan, efficacy, side effects, costs and the preference of the patient should be considered. A large amount of data available from randomized controlled trials permit the formulation of robust evidence-based recommendations for the treatment of anxiety disorders. The recommendations were not only developed for the special situation in Germany, but may also be helpful for developing treatment plans in other countries.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

CBT:

Cognitive behavioral therapy

DSM:

Diagnostic and Statistical Manual for Mental Disorders

GAD:

Generalized Anxiety Disorder

ITT:

Intention to treat

PDA:

Panic Disorder with or without Agoraphobia

PDT:

Psychodynamic therapy

RCT:

Randomized controlled trial

RIMA:

Reversible inhibitor of monoamine oxidase A

SAD:

Social Anxiety Disorder

SNRI:

Serotonin–noradrenaline reuptake inhibitor

SSRI:

Selective serotonin reuptake inhibitor

References

  1. APA (2009) Practice guideline for the treatment of patients with panic disorder. Work group on panic disorder. American psychiatric association, 2nd edn. American Psychiatric Press, Arlington

    Google Scholar 

  2. ÄZQ/AWMF (2008) Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI) 468–519

  3. Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R (2013) Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat 9:883–892

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, Christmas DM, Davies S, Fineberg N, Lidbetter N, Malizia A, McCrone P, Nabarro D, O’Neill C, Scott J, van der Wee N, Wittchen HU (2014) Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the british association for psychopharmacology. J psychopharmacol 28:403–439

    Article  PubMed  Google Scholar 

  5. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the british association for psychopharmacology. J psychopharmacol 19:567–596

    Article  CAS  PubMed  Google Scholar 

  6. Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, Moller HJ (2012) Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 16:77–84

    Article  CAS  PubMed  Google Scholar 

  7. Bandelow B, Wiltink J, Alpers GW, Benecke C, Deckert J, Eckhardt-Henn A, Ehrig C, Engel E, Falkai P, Geiser F, Gerlach AL, Harfst T, Hau S, Joraschky P, Kellner M, Köllner V, Kopp I, Langs G, Lichte T, Liebeck H, Matzat J, Reitt M, Rüddel HP, Rudolf S, Schick G, Schweiger U, Simon R, Springer A, Staats H, Ströhle A, Ströhm W, Waldherr B, Watzke B, Wedekind D, Zottl C, Zwanzger P, M.E. B (2014) S3-Leitlinie zur Behandlung von Angststörungen

  8. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Allgulander C, Ayuso-Gutierrez J, Baldwin DS, Buenvicius R, Cassano G, Fineberg N, Gabriels L, Hindmarch I, Kaiya H, Klein DF, Lader M, Lecrubier Y, Lepine JP, Liebowitz MR, Lopez-Ibor JJ, Marazziti D, Miguel EC, Oh KS, Preter M, Rupprecht R, Sato M, Starcevic V, Stein DJ, van Ameringen M, Vega J (2008) World federation of societies of biological psychiatry (WSFBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders—first revision. World J Biol Psychiatry 9:248–312

    Article  PubMed  Google Scholar 

  9. Broocks A, Bandelow B, Pekrun G, George A, Meyer T, Bartmann U, Hillmer-Vogel U, Ruther E (1998) Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry 155:603–609

    Article  CAS  PubMed  Google Scholar 

  10. Canadian Psychiatric Association (2006) Canadian psychiatric association clinical practice guidelines, management of anxiety disorders. Can J Psychiatry 58:1S–92S

    Google Scholar 

  11. DIMDI (2013) Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme, 10. Revision, German Modification (icd-10-gm)

  12. Dresler T, Guhn A, Tupak SV, Ehlis AC, Herrmann MJ, Fallgatter AJ, Deckert J, Domschke K (2013) Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder. J Neural Transm 120:3–29

    Article  CAS  PubMed  Google Scholar 

  13. Eccles M, Mason J (2001) How to develop cost-conscious guidelines. Health Technol Assess (Winchester, England) 5:1–69

    CAS  Google Scholar 

  14. GIN (2012) Guidelines international network. http://www.g-i-n.net/. Accessed 14 Nov 2014

  15. Gloster AT, Wittchen HU, Einsle F, Lang T, Helbig-Lang S, Fydrich T, Fehm L, Hamm AO, Richter J, Alpers GW, Gerlach AL, Strohle A, Kircher T, Deckert J, Zwanzger P, Hofler M, Arolt V (2011) Psychological treatment for panic disorder with agoraphobia: a randomized controlled trial to examine the role of therapist-guided exposure in situ in cbt. J Consult Clin Psychol 79:406–420

    Article  PubMed  Google Scholar 

  16. Heinrichs N, Alpers GW, Gerlach AL (2009) Evidenzbasierte Leitlinien zur Psychotherapie der Panikstörung mit und ohne Agoraphobie und der agoraphobie ohne Panikstörung im Auftrag der Fachgruppe Klinische Psychologie und Psychotherapie in der deutschen Gesellschaft für Psychologie (dgp). Hogrefe, Göttingen

    Google Scholar 

  17. Heinrichs N, Stangier U, Gerlach A, Willutzki U, Fydrich T (2010) Evidenzbasierte Leitlinie zur Psychotherapie der sozialen Angststörung. Hogrefe, Göttingen

    Google Scholar 

  18. Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6:65–70

    Google Scholar 

  19. Jacobi F, Hofler M, Strehle J, Mack S, Gerschler A, Scholl L, Busch MA, Maske U, Hapke U, Gaebel W, Maier W, Wagner M, Zielasek J, Wittchen HU (2014) mental disorders in the general population : study on the health of adults in germany and the additional module mental health (degs1-mh). Nervenarzt 85:77–87

    Article  CAS  PubMed  Google Scholar 

  20. Jacobi F, Wittchen HU, Holting C, Hofler M, Pfister H, Muller N, Lieb R (2004) Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German health interview and examination survey (ghs). Psychol Med 34:597–611

    Article  CAS  PubMed  Google Scholar 

  21. Kessler RC, Demler O, Frank RG, Olfson M, Pincus HA, Walters EE, Wang P, Wells KB, Zaslavsky AM (2005) Prevalence and treatment of mental disorders, 1990–2003. N Engl J Med 352:2515–2523

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the national comorbidity survey. Arch Gen Psychiatry 51:8–19

    Article  CAS  PubMed  Google Scholar 

  23. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU (2012) Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 21:169–184

    Article  PubMed Central  PubMed  Google Scholar 

  24. Moher D, Altman DG, Liberati A, Tetzlaff J (2011) Prisma statement. Epidemiology 22:128

    Article  PubMed  Google Scholar 

  25. NICE (2011) National institute for health and clinical excellence (nice). Anxiety: Management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. The British Psychological Society and The Royal College of Psychiatrists. www.nice.org.uk

  26. NICE (2013) National institute for health and clinical excellence (nice). Social anxiety disorder: Recognition, assessment and treatment (full guideline). The British Psychological Society and The Royal College of Psychiatrists

  27. Oyebode F, Rastogi A, Berrisford G, Coccia F (2012) Psychotropics in pregnancy: safety and other considerations. Pharmacol Ther 135:71–77

    Article  CAS  PubMed  Google Scholar 

  28. Priebe S, Wright D (2006) The provision of psychotherapy: an international comparison. J Public Ment Health 5:12–22

    Article  Google Scholar 

  29. SIGN (2012) Scottish intercollegiate guidelines network www.Sign.Ac.Uk

  30. Tuccori M, Testi A, Antonioli L, Fornai M, Montagnani S, Ghisu N, Colucci R, Corona T, Blandizzi C, Del Tacca M (2009) Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. Clin Ther 31(Pt 1):1426–1453

    Article  CAS  PubMed  Google Scholar 

  31. Udechuku A, Nguyen T, Hill R, Szego K (2010) Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry 44:978–996

    PubMed  Google Scholar 

  32. Wedekind D, Broocks A, Weiss N, Engel K, Neubert K, Bandelow B (2010) A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder. World J Biol Psychiatry 11:904–913

    Article  PubMed  Google Scholar 

  33. WHO (1991) World Health Organisation. Tenth revision of the international classification of diseases, chapter v (f): Mental and behavioural disorders (including disorders of psychological development). Clinical descriptions and diagnostic guidelines. World Health Organisation, Geneva

    Google Scholar 

  34. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:655–679

    Article  CAS  PubMed  Google Scholar 

  35. Wittchen HU, Kessler RC, Beesdo K, Krause P, Hofler M, Hoyer J (2002) Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 63(Suppl 8):24–34

    PubMed  Google Scholar 

Download references

Acknowledgments

The members of the guideline committee were as follows: Georg W. Alpers, Cord Benecke, Jürgen Deckert, Annegret Eckhardt-Henn, Christian Ehrig, Kerstin Engel, Peter Falkai, Franziska Geiser, Alexander L. Gerlach, Stephan Hau, Timo Harfst, Peter Joraschky, Michael Kellner, Volker Köllner, Gernot Langs, Heinz Liebeck, Jürgen Matzat, Markus Reitt, Heinrich Peter Rüddel, Gerhard Schick, Ulrich Schweiger, Regine Simon, Andreas Ströhle, Anne Springer, Hermann Staats, Walter Ströhm, Benedikt Waldherr, Birgit Watzke, Dirk Wedekind, Jörg Wiltink, Christian Zottl, and Peter Michael Zwanzger. The members of the steering committee were Borwin Bandelow, Manfred E. Beutel, Thomas Lichte, and Sebastian Rudolf. Moderation: Ina Kopp.

Conflict of interest

All participants in the guideline panel have declared their conflicts of interest (e.g., having received lecture honoraria from drug manufacturers or being a leading member of a group which advocates a particular form psychotherapy school). The guideline committee undertook every effort to base its recommendations exclusively on objective evaluation of the scientific evidence. Participants with a relevant conflict of interest abstained when recommendations on the treatment in question were put to a vote. Prof. Bandelow has served as a paid consultant to Lilly, Lundbeck, Otsuka, and Pfizer. He has received honoraria for lectures at scientific meetings and continuing medical education events from AstraZeneca, Glaxo, Janssen, Lilly, Lundbeck, Meiji-Seika, Otsuka, Pfizer, and Servier. Prof. Beutel has received payment from Pfizer, Servier, and Boehringer-Ingelheim for preparing scientific meetings and continuing medical education events. Dr. Rudolf, Prof. Lichte, and PD Wiltink declare that no conflict of interest exists.

Author information

Authors and Affiliations

  1. Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, University of Göttingen, von-Siebold-Str. 5, 37075, Göttingen, Germany

    Borwin Bandelow

  2. Institute of General Practice, Otto-von-Guericke University Magdeburg, Magdeburg, Germany

    Thomas Lichte

  3. Helios Clinic for Psychiatry and Psychosomatic Medicine, Schleswig, Germany

    Sebastian Rudolf

  4. Department of Psychosomatic Medicine and Psychotherapy, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany

    Jörg Wiltink & Manfred E. Beutel

Authors
  1. Borwin Bandelow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Lichte
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sebastian Rudolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jörg Wiltink
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Manfred E. Beutel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Borwin Bandelow.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bandelow, B., Lichte, T., Rudolf, S. et al. The German guidelines for the treatment of anxiety disorders. Eur Arch Psychiatry Clin Neurosci 265, 363–373 (2015). https://doi.org/10.1007/s00406-014-0563-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00406-014-0563-z

Keywords

Search

Navigation